Intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases: an updated systematic review
| Autor: | Anwar Giryes, Jan Schmidt, Michael Decker, Hani Oweira, Sarah El-Nakeep, Noha Rashad, Arianeb Mehrabi, Ulf Petrausch, D. Helbling, Omar Abdel-Rahman |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Time Factors Hepatic resection Colorectal cancer Antineoplastic Agents Kaplan-Meier Estimate Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Risk Factors medicine Humans Peritoneal Neoplasms Hepatology business.industry Liver Neoplasms Gastroenterology Intraperitoneal chemotherapy Cytoreduction Surgical Procedures medicine.disease Neoadjuvant Therapy Surgery Peritoneal carcinomatosis Treatment Outcome Combined modality Chemotherapy Adjuvant Curative treatment 030220 oncology & carcinogenesis Disease Progression 030211 gastroenterology & hepatology Colorectal Neoplasms Cytoreductive surgery business |
| Zdroj: | Expert Review of Gastroenterology & Hepatology. :1-10 |
| ISSN: | 1747-4132 1747-4124 |
| DOI: | 10.1080/17474124.2017.1284586 |
| Popis: | We aimed to assess the efficacy and safety of delivering intraperitoneal chemotherapy and cytoreductive surgery for peritoneal metastases coupled with curative treatment of colorectal liver metastases. Areas covered: A comprehensive literature search using PubMed was conducted to screen for eligible records. Studies evaluating colorectal surgery and intraperitoneal chemotherapy combined with curative treatment of liver metastases were included. We excluded duplicate publications. Sixty-seven full-text papers were assessed and six papers were finally included. The overall survival in the included studies ranged from 6-49 months. Five-year survival ranged from 18%-28%, three-year survival ranged from 22%-42% and two-year survival ranged from 34%-78%. Survival was lower in patients with liver metastases and peritoneal carcinomatosis (PC) than those with PC alone in the majority of studies. Expert commentary: This review poses questions rather than presenting answers. The heterogeneity of survival data suggests the possible benefit of this aggressive treatment approach in selected patients. Standardization of the technique used for intraperitoneal chemotherapy instillation, agent used as well as the systemic chemotherapy and targeted therapy type and duration through prospective controlled trials is required to provide an evidence of a higher strength to support or prohibit this treatment strategy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|